TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
CellSource Co., Ltd. ( (JP:4880) ) just unveiled an announcement.
CellSource Co., Ltd. reported its April 2025 KPI results, highlighting a stable daily average of processing orders at 58.5, consistent with March figures. Despite a slight decrease in orders for adipose-derived stem cell processing and non-orthopedic departments, the company maintained a steady number of blood-derived processing orders in its core orthopedic segment. The company noted a decrease in monthly orders for blood-derived products in both self-funded and hybrid orthopedics, with a 2.7% and 2.0% decline, respectively. However, they are focusing on strengthening their organizational structure and maintaining planned order volumes, while ongoing initiatives target key medical institutions.
The most recent analyst rating on (JP:4880) stock is a Buy with a Yen1600.00 price target. To see the full list of analyst forecasts on CellSource Co., Ltd. stock, see the JP:4880 Stock Forecast page.
More about CellSource Co., Ltd.
CellSource Co., Ltd. operates in the biotechnology industry, focusing on contract processing services, particularly in the field of stem cell processing. The company is listed on the Tokyo Stock Exchange and emphasizes its core operations in orthopedic segments.
Average Trading Volume: 67,705
Technical Sentiment Signal: Sell
Current Market Cap: Yen12.88B
Find detailed analytics on 4880 stock on TipRanks’ Stock Analysis page.